Bear, and let's not forget the fate of the ROFR in favour of Hepalink USA for the Apabetalone license in the USA. What's to come of it?
And to your last point, I'll add ...
Are they leaving the door open for performing an interim analysis and opening enrollment, particularly in the US of A ?
Koo